CD20 is a transmembrane phosphoprotein that is expressed on the surface of B lymphocytes.
The CD20 antigen is present on both resting and activated B lymphocytes but is lost prior to differentiation into plasma cells.

As CD20 expression is restricted to B cells, this antigen is a useful marker or target for B-cell lymphomas.

Studies demonstrate that the expression of CD20 correlates with B-cell lymphoma in dogs.
In human medicine, an anti-human CD20 monoclonal antibody (Rituximab) has been approved by the FDA to treat B-cell non-Hodgkin's lymphoma resistant to other chemotherapy regimens.


Human anti-CD20 antibodies

Anti-hCD20 isotype collectionCollection of antibodies, variable region of rituximab (anti-CD20)

Dog anti-CD20 antibodies

Anti-dCD20c1-dIgG2Monoclonal dog IgG2 antibody against dog CD20
Anti-dCD20c2-dIgG2Monoclonal dog IgG2 antibody against dog CD20
Anti-dCD20c3-dIgG2Monoclonal dog IgG2 antibody against dog CD20
Anti-dCD20c1-mIgG2aMonoclonal mouse IgG2a antibody against dog CD20
Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
Copyrights © 2011-2016 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "".